Parkinson's Disease | Emerging Therapies | Special Topics: Neurologists' Receptivity to Emerging Parkinson's Disease Treatments (US)

Publish date: April 2018

Login to access report

Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are not sufficient to control the virtually inevitable emergence of motor response complications in advanced stages of the disease. Opportunity in this arena has spurred the development of a range of new therapies targeting motor symptoms in PD. With the recent launches of Rytary, Xadago, and Gocovri, and with half a dozen others in late-phase development, understanding how prescribers perceive and plan to incorporate new brands is crucial for developers facing a complicated, highly genericized, and increasingly competitive market.

Questions Answered

  • How do neurologists currently prescribe or plan to prescribe recently launched brands (i.e., Rytary, Xadago, and Gocovri)?
  • How do surveyed neurologists plan on incorporating late-phase therapies into the treatment algorithm?
  • What are the top reasons why some neurologists do not prescribe or would refrain from prescribing recently launched or emerging brands?
  • How will the availability of new PD brands impact current prescribing in PD? How will generic Rytary impact the use of current and emerging PD therapies?

Product Description

DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on Parkinson’s disease will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.

Markets covered: United States

Primary research: Survey of 101 U.S. neurologists

Key companies: Impax Laboratories, Intec Pharma, NeuroDerm, Mitsubishi Tanabe Pharma, US WorldMeds, Newron Pharmaceuticals, Bial, Adamas Pharmaceuticals, Acorda Therapeutics, Sunovion Pharmaceuticals, Sumitomo Dainippon Pharma

Key drugs: Rytary, AP-CD/LD, ND-0612, apomorphine pump, Xadago, Ongentys, Gocovri, Inbrija, APL-130277, Apokyn

Key insights provided:

  • Willingness to prescribe key emerging therapies.
  • Current/anticipated use of newly launched and emerging therapies and their impact on current treatment.
  • Key obstacles to uptake of newly launched and emerging therapies.
  • Potential uptake of emerging therapies into key PD subpopulations with motor complications.

Table of contents

  • Special Topics: Neurologists' Receptivity to Emerging Parkinson's Disease Treatments (US)
    • Special Topics - Neurologists' Receptivity to Emerging Parkinson's Disease Treatments (US)

Author(s): Bethany Christmann, PhD

Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.